Reviewing Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) and Autolus Therapeutics (NASDAQ:AUTL)

Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) and Autolus Therapeutics (NASDAQ:AUTL) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability and valuation.

Institutional & Insider Ownership

64.8% of Autolus Therapeutics shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Hansa Biopharma AB (publ) and Autolus Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hansa Biopharma AB (publ)	N/A	N/A	N/A
Autolus Therapeutics	N/A	-64.86%	-35.01%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Hansa Biopharma AB (publ) and Autolus Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hansa Biopharma AB (publ)	0	0	0	0	N/A
Autolus Therapeutics	0	0	7	0	3.00

Autolus Therapeutics has a consensus price target of $8.17, suggesting a potential upside of 85.19%. Given Autolus Therapeutics’ higher possible upside, analysts plainly believe Autolus Therapeutics is more favorable than Hansa Biopharma AB (publ).

Earnings & Valuation

This table compares Hansa Biopharma AB (publ) and Autolus Therapeutics’ top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hansa Biopharma AB (publ)	N/A	N/A	N/A	($0.87)	-3.47
Autolus Therapeutics	$5.52 million	138.20	-$148.84 million	($0.98)	-4.50

Hansa Biopharma AB (publ) has higher earnings, but lower revenue than Autolus Therapeutics. Autolus Therapeutics is trading at a lower price-to-earnings ratio than Hansa Biopharma AB (publ), indicating that it is currently the more affordable of the two stocks.

Summary

Autolus Therapeutics beats Hansa Biopharma AB (publ) on 5 of the 9 factors compared between the two stocks.

About Hansa Biopharma AB (publ)

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments with rare immunological conditions using its proprietary enzyme technology platform. The company's lead drug candidate is Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the potential of combining imlifidase and efgartigimod to potentially be used in the acute and chronic setting of autoimmune diseases and transplantation. It also has a collaboration with Genethon to develop imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.